TNF-α inhibitors (TNFαi) adalimumab and infliximab were approved for GIBD management in Japan in 2013 and 2015, respectively, and use for patients who fail to respond to conventional treatments has been incorporated into recent updates of the Japanese BD guidelines [12, 16–19]. This evidence concerns the gene TNF and Behcet disease.